A Tentative Staging of Multiple Myeloma by Utilizing Respective Coefficients of Prognostic Factors

Authors

  • Hasan Jalaeikhoo AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran
  • Manoutchehr Keyhani Hematology and Oncology Research Center, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  • Mohammad Zokaasadi AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran
  • Mohsen Rajaeinejad AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran
  • Morteza Sharifzadeh AJA Cancer Epidemiology Research and Treatment Center (AJA- CERTC), AJA University of Medical Sciences, Tehran, Iran
Abstract:

Introduction: Multiple myeloma is a heterogeneous disease with different survival times among patients. Accurate prediction of prognosis in multiple myeloma is essential, as patients with a shorter survival time may require early bone marrow transplantation (BMT) and more advanced chemotherapy as a part of their first-line treatment. In the present study, a parameter, depicted by gamma (γ) symbol, was utilized to categorize patients into different stages. Gamma value is equal to the summation of each prognostic factor multiplied by its corresponding beta coefficient. This parameter has been previously studied for the staging of some malignancies, such as “Nottingham Prognostic Index” for breast cancer and “Prognostic Score” for parotid carcinoma. Methods: One hundred forty-three cases were randomly divided into two groups. Beta coefficients for prognostic factors, including creatinine, calcium, and albumin, were obtained from multivariate Cox analysis in the first group. In this group, a staging system based on patients’ gamma parameters was defined followed by the evaluation of the accuracy of this staging system in the second group. Results: The staging system that developed from the first group was suitable for the prediction of outcomes in the second group. The patients of the second group were divided into approximately equal numbers in each stage comprising 29, 24, and 18 cases in stage 1, 2, and 3, respectively. In this group, the median overall survival (OS) values for patients in each stage were 92, 57, and 22 months, respectively, with log-rank = 0.002. Conclusions: The proposed method demonstrated promising results for myeloma prognostication. The authors believe this approach would increase the strength and validity of staging of multiple myeloma.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Prognostic factors in multiple myeloma.

All patients with multiple myeloma seen over a 9-year period at Tygerberg Hospital were studied retrospectively. Presentation data of 144 patients, as well as individual laboratory results were included in the survival analysis. Cox's proportional hazard model (a non-parametric multivariate regression method) was used to predict survival and divide patients into prognostic groups. The relations...

full text

Prognostic variables and clinical staging in multiple myeloma.

To evaluate the most important factors in the prognosis and staging of multiple myeloma (MM), the presenting clinical features of 163 previously untreated patients with MM were correlated with survival duration using univariate and multivariate regression analyses. The univariate proportional hazard analysis ranked the parameters in the following order of importance: platelet count, hemoglobin ...

full text

Prognostic Factors in Patients with Multiple Myeloma

That is why the morphology of myeloma cells is one of the most important prognostic factors of the disease [4]. There are also other prognostic factors associated with both malignant cell characteristics and the status of the host's immunocompetent system [7]. Taking into account the data on the decrease in colony-forming units granulocyte/macrophage (CFU-OM) in MM [2, 11], an~ the antitumor ef...

full text

Treatment of Multiple Myeloma

Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue.  La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours. 

full text

The Evolution of Prognostic Factors in Multiple Myeloma

Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease. Despite improvement in treatment strategies of MM over the last decade, the disease remains incurable. All efforts are currently focused on understanding the prognostic markers...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 2  issue None

pages  22- 25

publication date 2018-03

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023